Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Generic Line > Teva Sues Perrigo, Catalent to Halt ANDA Plans for Asthma Drug

Generic Line

Sept. 12, 2012 | Vol. 29 No. 18

Teva Sues Perrigo, Catalent to Halt ANDA Plans for Asthma Drug

Teva is suing Perrigo and Catalent Pharma Solutions to stop the companies’ plans to market and develop generic versions of its asthma drug ProAir HFA before two key patents pop.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Briefs Perrigo Can Launch Ofirmev Generic in 2020, May Get Authorized Generic Deal Perrigo Can Launch Ofirmev Generic in 2020, May Get Authorized Generic Deal Abbott Hits Watson With Second Suit Against Expanded Niaspan ANDA

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.